Value Proposition canvas- Customer needs and pains
H.A.E.Konarowski, Chemrar High-Teck Center
1. 1 st International Conference on Innovative Growth for Pharmaceutical and Medical Industry in Russia. Integrating Academic and Industrial Science MIPT, 12 May 2011 Henrik A. E. Konarkowski ChemRar High Tech Center www.chemrar.ru
20. Передача лицензии на территорию России Проведение доклиники или клиники в РФ Производство инновационного препарата в РФ Передача результатов клинических исследований Коммерциализация за рубежом Руб. Кросс-Роялти % Финансирование От Российских партнеров Модель трансферта разработок инновационных лекарственных средств $$$ Иностранный партнер Российский партнер Иностранный партнер Российский партнер
21.
22.
23. CSC starts chemistry servies in Russia CHEMRAR incorporat. New Research Institute in Khimki, Moscow licensed 1st Russian Patent in liquid crystal technology to Hoffmann La Roche, Basel Formulation, Pilot GMP, API with MIT support The first LP in Western VC incorporation CITOLEX – first manufacturing project in RUSSIA ID - first biotech in Yaroslavl Univ. with Federal Innov. agency support Clinical Research Organization Health Care Ventures IX The first IP transfer project with ROCHE The first biotech in USA JV with RUSNANO ($160M venture project) Active partnering with few Life Science Venture funds 84 90 95 00 05 07 08 09 10 Open labs in San Diego CA New wave as RVC partner 11 04
24. From 2008 ChemRar experts prominently participated in drafting of the “Russian Federation Innovative Development Strategy for the Pharmaceutical Industry through the year 2020” (Pharma2020). December , 2010: Prime Minister Vladimir Putin visiting ChemRar with Ministers of Industy and Health
25. Bringing into Russia innovative development projects at various stages, from Biotarget stage, to clinical candidates, and developing them into Medicines In-Partnering Development Projects Globally 20 years, more than 1200 partners
26. first line Service Research Organizations Biotech Companies Manufacturing & Market Access
![[object Object],[object Object],[object Object],[object Object],THE COST OF A DELAY DAY (SELECT BLOCKBUSTER DRUGS) Note: The average drug generates $1.3 million sales daily Source: IMS Health, 2002 and PhRMA Profile, March 2007 The Cost of Developing a Drug](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)